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Abstract The aim of this study was to describe vaso-
reactivity (by Acetylcholine and Methergine tests) at
2 year follow-up in parallel with the individual changes
in the echogenicity characteristics of the polymer struts
of the everolimus eluting bioresorbable vascular scaf-
fold (BVS), from post-treatment to 2 year follow-up,
in patients enrolled in the ABSORB Cohort A study.
Intravascular ultrasound assessment was performed
with a phased array catheter (EagleEye, Volcano
Corporation, Cordova, CA, USA) with automated
pullback at 0.5 mm per second. The % ratio at 6 months
and 2 years [(Scaffold Area post PCI- Lumen Area)/
Scaffold Area post PCI] was calculated as a measure of
scaffold shrinkage. The % change of hyperechogenicity
was defined as: ([post-procedural hyperechogenici-
ty] - [2 year follow up hyperechogenicity])/[post-pro-
cedural hyperechogenicity]) 9 100. The vasomotion
test with intracoronary acetylcholine (10-6 M) or
intravenous methergine (0.4 mg) was performed at
2 years. Overall nine patients received all these analyses
and were enrolled in the present analysis. A 50–96%
reduction in hyperechogenicity was observed between
baseline and 2 years, which corresponded to a change in
vasoreactivity between 2 and 22%. A vasoconstriction
of the scaffolded segment was observed in the 5 patients,
who underwent the methergine test, with a mean
decrease in lumen diameter after methergine of
9 ± 7% (P = 0.06), while vasodilatation occurred in
the 4 patients who underwent the acetylcholine test with
a mean increase in lumen diameter after acetylcholine of
8 ± 5% (P = 0.125). Bioresorption of the BVS is
accompanied by re-establishment of both endothelial
and non-endothelial dependent vasomotion.
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Introduction
The everolimus eluting Bioresorbable Vascular Scaf-
fold (BVS) (Abbott Vascular, Santa Clara, CA, USA)
is expected to perform similar to a metal stent post
implantation by preventing acute recoil, providing a
scaffold to the vessel during healing, and then being
completely bioresorbed within 2–3 years [1]. The
advantages of using bioresorbable scaffolds are the
potential for the restoration of normal vascular
function once the bioresorption process has been
completed such that vessels can once again react to
pulsatile flow, positively remodel and respond nor-
mally to endothelial factors.
In the ABSORB A clinical study echogenicity
assessment, with grey-scale intra-vascular ultrasound
(IVUS) computer aided analysis, has shown a significant
reduction in percent hyperechogenic tissue between
post-procedure and 6 month follow-up, with a further
reduction observed between 6 months and 2 year
follow-up [2]. The same study also demonstrated the
restoration of vasomotion within the scaffolded and
peri-scaffolded segments in response to acetylcholine
and methergine at 2 year follow-up [2].
Amongst those patients enrolled in the ABSORB
A study there has been no detailed comparison as yet
on an individual patient level of the vasomotion and
echogenicity changes from post-procedure to 2 year
follow-up. The aim of this study was to describe
vasoreactivity at 2 years (by Acetylcholine and
Methergine tests) in parallel with the individual
changes in the echogenicity characteristics of the
polymer struts of the BVS, from post-treatment to
2 year follow-up, using a computer aided grey scale
value analysis program, in patients enrolled in the
ABSORB A study.
Methods
Patient population
The ABSORB Cohort A study design has been
already described previously [1]. Briefly, in this
single-arm, prospective study 30 patients, with a
diagnosis of stable or unstable angina or silent
ischemia, were enrolled in four participating centres
between March and July 2006. All treated lesions
were single, de novo lesions in a native coronary
artery of 3.0 mm, shorter than 8 mm for the 12 mm
device and shorter than 14 mm for the 18 mm device,
with a diameter stenosis greater than 50% and less
than 100%, and with a thrombolysis in myocardial
infarction (TIMI) flow grade more than 1. Major
exclusion criteria were patients with an acute myo-
cardial infarction or unstable arrhythmias, those who
had a left ventricular ejection fraction less than 30%,
restenotic lesions, lesions located in the left main
coronary artery, lesions involving a side branch more
than 2 mm in diameter, and the presence of thrombus
or another clinically significant stenosis in the target
vessel. The protocol was approved by the ethics
committee at the four participating centres. All
enrolled patients signed a written informed consent.
Angiography, IVUS and derived IVUS parameters
(virtual histology, palpography and echogenicity)
were assessed at 6 month and 2 year follow-up.
Vasomotion testing with acetylcholine or methergine
was performed at 2 years.
Study device
The BVS revision 1.0 has a polymer backbone of
Poly-L (racemic)-lactic acid (PLLA) coated a thin
layer of a 1:1 mixture of an amorphous matrix of
Poly-D,L (racemic)-lactic acid (PDLLA) polymer,
and 100 micrograms/cm2 of the anti-proliferative
drug everolimus. Both PLLA and PDLLA are fully
absorbable. The polymer degrades via a bulk erosion
process through hydrolysis of the ester bonds in the
backbone. The resulting lactic acid oligomers even-
tually leave the polymer matrix and are metabolized
in surrounding tissues and blood into the pyruvate
and Kreb’s energy cycles. Small particles\2 microns
in diameter are phagocytosed by macrophages. The
time for complete absorption of the polymer back-
bone is predicted from preclinical studies to be about
2 years whereas the polymer coating is absorbed in a
faster timeframe. The implant is radiolucent, but has
two platinum markers at each end that allow easy
visualization on angiography and with other imaging
modalities.
Quantitative coronary angiography (QCA)
and vasomotion test
QCA was performed with the CAAS II analysis sys-
tem (Pie Medical BV, Maastricht, The Netherlands)
Int J Cardiovasc Imaging
123
by an independent central research organization (Car-
dialysis B.V., Rotterdam, The Netherlands). The
following QCA parameters were computed for the
scaffolded segments and the proximal and distal
references: minimal lumen diameter, reference vessel
diameter, percent diameter stenosis, and lesion length.
The accuracy of this method has been reported in detail
previously [3]. The scaffolded segment was defined as
the segment between the 2 radio-opaque platinum
markers on both ends of the BVS.
To study vasomotion at 2 years, either the endo-
thelium independent vasoconstrictor methylergo-
metrine maleate (methergine, Novartis, Basel,
Switzerland), or the endothelium dependent acetyl-
choline (Ovisot, Daiichi-Sankyo, Tokyo, Japan) was
given, dependent on local practice. Calcium channel
blockers and nitrates were withheld at least 48 h
before the coronary angiogram. Mean lumen diam-
eter in the scaffolded segment was measured by QCA
after a baseline infusion of saline, and a sub-selective
intracoronary administration of acetylcholine infused
through a microcatheter at increasing dose up to 10-6
M. For the methergine test, QCA was measured
5 min after an intravenous bolus injection of mether-
gine (0.4 mg). Both tests were terminated by intra-
coronary administration of 200 lg of nitroglycerin
(nitronal, Pohl-Boskamp GmbH, Hohenlockstedt,
Germany).
The two vasomotion tests produce two different
responses in normal coronaries: vasodilation by
Acetylcholine, vasoconstriction by Methergine. Me-
thergine stimulates both alpha-adrenergic and sero-
tonergic receptors and therefore exerts a direct
constrictive effect on vascular smooth cells [4].
Acetylcholine infusion in the coronary artery causes
the release of NO through activation of the
muscarinic receptor on the surface of the endothe-
lial cell with consequent relaxation of the smooth
muscle cell and therefore vasodilation. This mech-
anism is disturbed in case of endothelial dysfunc-
tion, where a paradox vasoconstriction may be
observed [5, 6], due to the direct activation of
muscarinic receptors on the surface of smooth
muscle cells.
Intravascular ultrasound
Intravascular ultrasound (IVUS) assessment was
performed with a phased array catheter (EagleEye,
Volcano Corporation, Cordova, CA, USA) with
automated pullback at 0.5 mm per second. The
region beginning 5 mm distal to and extending
5 mm proximal to the scaffolded segment was
examined. The following parameters were measured
with a computer-based contour detection software
(Curad, version 3.1): [7, 8] vessel area, scaffold area,
lumen area, neointimal area and luminal area steno-
sis. The appearance of the BVS struts on IVUS has
been clearly defined previously [7]. The percentage
ratio at 6 months [(Scaffold Area post PCI- Lumen
Area at 6 months)/(Scaffold Area post PCI)] was
calculated as a measure of scaffold shrinkage [9].
At 2 year follow up as a consequence of biore-
sorption the majority of struts were not visible on
IVUS grey-scale imaging; thus the scaffold area at
this time was assumed to be equal to the luminal area.
Automated echogenicity
A computer-aided grey-scale value analysis pro-
gramme [9, 10] was used to assess the echogenicity
of the polymeric struts after treatment, at 6 month
and at 2 year follow up. The applied algorithms of
this software have been previously published [10].
The mean grey-value of the adventitia is used to
classify tissue components as either hypechogenic
(e.g., grey-values lower than the mean adventitia
level) or as hyperechogenic (e.g., grey-values at
higher levels than that of the adventitia). The final
automated echogenicity quantification was measured
at each cross-section and hyper- and hypo-echoge-
nicity tissues were colour coded in green and red,
respectively. The difference (D) between the 2 year
follow up and the post-procedural hyperechogenicity
percentage was assessed in the treated segment.
The percentage change of hyperechogenicity was
defined as: {([post-procedural hyperechogenicity] -
[2 year follow up hyper-echogenicity])/[post-proce-
dural hyperechogenicity]} 9 100.
Statistics
Binary variables are presented as percentages. Con-
tinuous variables are presented as mean ± SD. Paired
comparisons between the post-procedure, 6 month
and the 2 year follow-up of IVUS parameters were
done by Friedman’s test and Dunn’s post-test for
multiple comparisons of all pairs.
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Paired comparisons between hyperechogenicity
and vasomotion data were done by a Wilcoxon
matched pairs test. Taking into account the small
sample size, P values presented in this paper are
exploratory and should therefore be interpreted with
caution.
Results
The patient demographics are shown in Table 1. All
patients were on secondary prevention with statins.
At 2 year clinical follow-up all patients were asymp-
tomatic and there were no reported major adverse
cardiac events (MACE). Table 2 shows IVUS
results on a patient level from post-procedure,
6 month and 2 year follow-up. The mean vessel area
was 12.64 ± 3.72 mm2 post-procedure, 13.22 ±
3.47 mm2 at 6 months; and 12.32 ± 3.74 mm2 at
2 years; P = NS. The mean lumen area was
6.17 ± 1.01 mm2 post-procedure, 5.45 ± 1.28 mm2
at 6 months, and 6.05 ± 1.73 mm2 at 2 years; P = NS.
The complete dataset of vasomotion and echoge-
nicity was available in 9 patients enrolled in the
ABSORB A trial (Table 3).
Four patients showed no significant intimal hyper-
plasia ranging from 0.42 to 0.71 mm2 at 6 month
follow-up.
Seven patients showed an enlargement of the mean
lumen area ranging from 0.64 to 1.85 mm2 at 2 years,
without significant changes in the mean vessel area.
The percentage ratio at 6 months [(Scaffold Area
post PCI - Lumen Area at 6 months)/(Scaffold Area
post PCI)] ranged between -7.42 and 28; whilst the
percentage ratio at 2 years [{(scaffold area post-
PCI) - (lumen area at 2 years)}/(scaffold area post-
PCI)] was in the range of -27–50%, P = 0.31.
Of note, two patients (pt 8, 9) showed a percentage
ratio at 6 months [(Scaffold Area post PCI - Lumen
Area at 6 months)/(Scaffold Area post PCI)] of 26
and 28%, respectively. At 2 year follow-up the ratio
in patient 8 decreased from 26 to 5%, whilst in
patient 9 the ratio increased from 28 to 50%. There
was no evidence of intimal hyperplasia in either of
these 2 patients at 6 months.
The IVUS echogenicity and vasomotion findings
on a patient level are shown in Table 3.
The mean hyperechogenicity percentage in all
patients was 21 ± 12% (range: 5–38) post-procedure
and 6 ± 6% (range: 0–19) at 2 year follow up, with a
mean percentage change of 77 ± 17% (range: 50–96,
P = 0.004). The residual level of hyperechogenicity
at 2 years was similar to the natural hyperchogenicity
of plaque pre-procedure (6 ± 6% vs. 6 ± 5%).
The vasomotion test at 2 years showed vasocon-
striction of the scaffolded segment in the 5 patients
who underwent the methergine test, with a mean
decrease in lumen diameter after methergine of
-9 ± 7% (P = 0.06), while vasodilatation occurred
in the 4 patients who underwent the acetylcholine test
with a mean increase in lumen diameter after
acetylcholine of 8 ± 5% (P = 0.125). Patient 9,
who had a ratio [((scaffold area post-procedure)
- (lumen area at 2 years))/(scaffold area post-proce-
dure)] of 50% at 2 year follow-up showed the
smallest response to acetylcholine with a change of
only 2%, and a difference in mean lumen diameter
of 0.03 mm between baseline and after infusion
Table 1 Clinical characteristics
Sex Age Hypercholesterolemia Hypertension Smoker Diabetes Prior MI Prior PCI SA UA
Pt 1 Female 69 Yes Yes No No No No No Yes
Pt 2 Male 58 No Yes No No No No No Yes
Pt 3 Male 72 No No No No No No Yes No
Pt 4 Male 60 Yes Yes No No No No Yes No
Pt 5 Female 47 Yes Yes No No No No Yes No
Pt 6 Male 70 No No No No No No No Yes
Pt 7 Female 61 Yes Yes No No Yes No No Yes
Pt 8 Male 66 Yes Yes No No No No Yes No
Pt 9 Male 78 No No No No No No No Yes
MI myocardial infarction, PCI percutaneous coronary intervention, Pt patient, SA stable angina, UA unstable angina
Int J Cardiovasc Imaging
123
of acetylcholine. In this patient a decrease in the
mean lumen diameter after nitrates was also observed
in the scaffolded segment, and in the 5 mm segments
proximal and distal to the scaffold (Fig. 1).
A 50–96% reduction in hyperechogenicity was
observed between baseline and 2 years and this
corresponded to a change in vasomotion of between
2 and 21%.
Discussion
The main finding of this study is that the bioresorption
of the BVS is accompanied by the re-establishment of
endothelial and non-endothelial dependent vasomo-
tion. The bioresorption of the implant, as assessed by
echogeniticity, is concomitant with lumen area
enlargement at 2 years, and occurs without significant
Table 2 IVUS findings post-BVS implantation, at 6 month and 2 year follow-up
Post-BVS implantation 6 Month follow-up 2 Year follow-up
VA
(mm2)
SA
(mm2)
PA
(mm2)
VA*
(mm2)
SAT–
(mm2)
LA*
(mm2)
IH
(mm2)
PA
(mm2)
(SA post PCI-
LA 6mo)/SA
post PCI (%)
VA§d
(mm2)
LA§d
(mm2)
PA&
(mm2)
(SA post PCI-
LA 2 y)/SA
post PCI (%)
Pt 1 16.93 7.80 9.13 16.99 7.64 7.11 0.54 9.88 2 15.91 7.75 8.16 1
Pt 2 19.40 7.23 12.17 17.67 6.66 6.16 0.5 11.51 8 16.02 7.05 8.97 2
Pt 3 11.01 5.66 5.35 14.26 6.08 6.08 0 8.18 -7 13.62 5.75 7.87 -1
Pt 4 14.64 6.57 8.07 16.17 6.70 6.70 0 9.47 -2 15.74 6.85 8.89 -4
Pt 5 12.34 6.15 6.19 13.03 5.96 5.96 0 7.07 3 13.64 7.81 5.83 -27
Pt 6 10.47 5.73 4.74 11.04 4.84 4.75 0.42 6.29 15 10.04 5.17 4.87 10
Pt 7 10.53 6.21 4.32 11.50 5.54 4.84 0.71 6.66 11 7.72 6.28 1.44 -1
Pt 8 11.15 5.98 5.17 11.64 4.43 4.43 0 7.21 26 12.45 5.7 6.75 5
Pt 9 7.30 4.24 3.06 6.70 3.05 3.05 0 3.65 28 5.71 2.13 3.58 50
Dunn’s post-test multiple comparison for all pairs: * P value 6 Month Follow-up versus post-implantation = NS; § P value 2 year
Follow-up versus post-implantation = NS; d P value 2 year versus 6 Month follow-up = NS; T– P value versus post-
implantation \ 0.05; & P value 2 year versus 6 Month follow-up \ 0.05
IH intimal hyperplasia, LA lumen area, PA plaque area, SA scaffold area
Table 3 Post-implantation and 2 year follow-up IVUS based hyperechogenicity and vasomotion test at 2 years
Hyperechogenicity (%) Angiographic mean lumen diameter (mm) of the scaffolded
segment after methergine or acetylcholine* test
Post-implantation §2 years follow-up % change Baseline dMeth/Ach* % change after Meth/Ach
Patient 1 16 6 65 2.61 2.52 -3
Patient 2 5 0 96 2.64 2.08 -21
Patient 3 35 7 80 2.31 2.10 -9
Patient 4 11 5 59 2.57 2.35 -9
Patient 5 12 0 93 2.98 2.84 -5
Patient 6 16 1 92 1.90* 2.16* 14
Patient 7 33 11 67 1.81* 1.96* 8
Patient 8 38 19 50 2.47* 2.70* 9
Patient 9 25 2 93 1.29* 1.32* 2
* Acetylcholine test, § P value \ 0.05, post-implantation versus 2 year follow-up
d P value \ 0.05, Meth/Ach versus baseline
Ach acetylcholine, Meth methergine
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changes in the vessel area between 6 months and
2 years.
Despite this, it is unclear if the plaque reduction
that occurs between 6 months and 2 years after the
device implantation is the result of the mass loss due
to the bioresorption process, and/or an actual
decrease in the pre-scaffolding atherosclerotic pla-
que. Both situations could potentially explain the
plaque shrinkage that was observed in these patients.
Preclinical studies in the atherosclerotic rabbit model
have shown that the implantation of metallic everol-
imus eluting scaffold results in a reduction of
macrophages that is resulting from the triggering of
an autophagic process through the mTor pathway
inhibition by everolimus [11, 12]. Porcine histolog-
ical studies 3 years after BVS device implantation
have shown that the voids in the vessel wall that were
previously occupied by the polymeric struts were still
preserved but filled by proteoglycan material and a
mineralization process was observed around them
[2]. A further evaluation of these observations in
relation to the pre-scaffolding atherosclerotic plaque
would be useful to clarify the exact mechanism
underlying the plaque shrinkage.
Our observations support the hypothesis that in the
future the introduction of bioresorbable scaffolds
could potentially overcome the three main mecha-
nisms leading to the in-scaffold/vessel restenosis:
acute recoil, constrictive vessel remodelling and neo-
intimal hyperplasia.
In vivo acute recoil of the first generation BVS
was slightly larger (6.9 ± 7.0% vs. 4.3 ± 7.1%,
P = 0.25) but insignificantly different from that of
the metallic everolimus eluting stent (EES), implying
the radial strength of the BVS was similar to that of a
metallic stent [13].
At 2 year follow-up the vasoreactivity to endothe-
lial dependant and non-endothelial dependant agents
was restored in eight of the nine patients. Patient 9
was the only subject who did not sufficiently
Fig. 1 Mean Lumen
individual changes after
Methergine or
Acetylcholine and after
final nitrates administration
at 2 year follow-up
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vasodilate (\3%) after an infusion of acetylcholine.
This may have been anticipated considering the
angiographic and IVUS findings in this patient
(Fig. 2), which demonstrated a reduction in vessel
and lumen area, and the presence of calcium within
the treated segment.
The re-establishment of vasoreactivity after bior-
esorption of the scaffold could potentially lead to a
decreased risk of stent thrombosis. The restoration of
the vessel wall reactivity may ensure a normal
response to shear stress in the scaffolded and peri-
scaffold segments. This could facilitate a risk free
discontinuation of dual anti-platelet therapy, and
could prevent plaque progression.
The main limitation of this study is the small
sample size. In the ABSORB Cohort A study the
sample size was not defined on the basis of an
endpoint hypothesis, but rather to provide informa-
tion about the feasibility of the study and device
safety. Therefore this sub-study should be seen as
hypothesis-generating. The potential advantages of
this drug-eluting bioresorbable implant are currently
being assessed with a second-generation device in the
ABSORB Cohort B study. This device, BVS revision
1.1, has a polymer that is processed differently so that
its integrity and radial force can be retained for a
longer time. The improved design- zigzag hoops
linked by straight bridges- should provide a more
uniform vessel support and drug application. The
study will enrol 80 patients, with an acetylcholine test
in all patients at 2 year follow-up. Therefore we
expect to clarify the correlation between scaffold
bioresorption and the restoration of vasoreactivity in
the near future.
Fig. 2 Panel a presents a RAO Caudal angiographic image
after ABSORB device (3.0 9 12 mm, white line) implantation
on the Obtuse Marginal of the LCX; the post-procedural
Intravascular Ultrasound longitudinal pullbacks (b, c) show the
scaffold (yellow lines) and the frame (white line) corresponding
to the cross-sectional image (d) on the top right with the color-
coded hyperchogenicity on the bottom (e). The BVS struts are
color coded as green. On the bottom left (f) the 2 year follow-
up angiographic image shows a decreased lumen diameter of
the scaffolded region (white line). This finding is confirmed on
the intravascular ultrasound longitudinal pullbacks (g, h). The
IVUS cross-sectional image (i) on the bottom right shows a
reduced lumen area, the bioresorption of the BVS device struts
is almost completed and no hyperechogenic tissue components
are identified (j)
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Conclusions
The bioresorption of the BVS is accompanied by re-
establishment of both endothelial and non-endothelial
dependent vasomotion. This is concomitant with
lumen area enlargement without significant changes
in the vessel area.
The ABSORB Cohort A study has proved the
safety and feasibility of the everolimus eluting BVS.
Our results support the hypothesis that in the near
future the introduction into clinical practice of
bioresorbable scaffolds could represent a real break-
through in the field of interventional cardiology.
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